Grufity logoGrufity logo

Bausch Health Companies Inc. Stock Research

BHC

7.45USD-0.13(-1.72%)Market Closed

Market Summary

USD7.45-0.13
Market Closed
-1.72%

BHC Alerts

BHC Stock Price

BHC RSI Chart

BHC Valuation

Market Cap

2.7B

Price/Earnings (Trailing)

-11.98

Price/Sales (Trailing)

0.33

EV/EBITDA

0.78

Price/Free Cashflow

-2.85

BHC Price/Sales (Trailing)

BHC Profitability

EBT Margin

-1.59%

Return on Equity

-86.54%

Return on Assets

-0.88%

Free Cashflow Yield

-35.09%

BHC Fundamentals

BHC Revenue

Revenue (TTM)

8.1B

Revenue Y/Y

-0.14%

Revenue Q/Q

7.18%

BHC Earnings

Earnings (TTM)

-225.0M

Earnings Y/Y

-694.2%

Earnings Q/Q

-202.76%

Price Action

52 Week Range

4.0023.97
(Low)(High)

Last 7 days

-4.4%

Last 30 days

-15.9%

Last 90 days

17.7%

Trailing 12 Months

-68.4%

BHC Financial Health

Current Ratio

1.08

Debt/Cashflow

-0.05

BHC Investor Care

Shares Dilution (1Y)

0.69%

Diluted EPS (TTM)

-0.62

Peers (Alternatives to Bausch Health Companies)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
396.9B
94.9B
-4.42% -11.67%
22.12
4.18
1.25% -14.07%
298.8B
28.5B
1.30% 17.85%
47.85
10.47
0.79% 11.88%
272.8B
59.3B
-5.09% 32.83%
17.88
4.63
21.72% 11.27%
226.2B
100.3B
-5.50% -20.78%
7.21
2.25
23.43% 42.74%
142.4B
46.2B
-5.97% -4.10%
22.5
3.08
-0.49% -9.54%
MID-CAP
4.5B
4.5B
-8.55% -11.11%
-32.05
1.01
7.56% -104.06%
3.2B
2.2M
109.33% 133.59%
-10.15
1.4K
-80.71% -4.88%
SMALL-CAP
1.9B
667.2M
-10.48% 10.28%
30.48
2.77
15.09% 13.64%
1.6B
602.5M
-5.76% -54.20%
-2.78
2.67
18.18% -18.59%
923.6M
478.9M
-20.83% -73.20%
-0.29
1.93
-31.50% -634.70%
772.8M
285.2M
-9.04% -42.36%
3.51
2.71
-27.21% -40.28%
726.9M
114.5M
-12.79% -47.96%
-4.31
6.35
27.90% 57.40%
539.5M
29.8M
-36.94% -53.16%
-6.21
18.13
340.05% 4.35%
379.1M
51.5M
-14.46% -5.94%
-5.34
7.36
18.32% -984.05%
94.1M
2.3B
-43.99% -88.43%
-0.03
0.04
-22.53% -376.66%

Financials for Bausch Health Companies

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue0.0%8,124,000,0008,127,000,0008,192,000,0008,325,000,0008,434,000,000
  S&GA Expenses-0.5%2,625,000,0002,639,000,0002,631,000,0002,640,000,0002,624,000,000
EBITDA-13.3%2,729,000,0003,146,000,0002,936,000,0002,406,000,000-
EBITDA Margin-13.2%0.340.390.360.29-
Earnings Before Taxes-151.8%-129,000,000249,000,00026,000,000-515,000,000-1,024,000,000
EBT Margin-151.8%-0.020.030.00-0.06-
Interest Expenses-2.4%1,464,000,0001,500,000,0001,466,000,0001,420,000,0001,426,000,000
Net Income-188.6%-225,000,000254,000,00043,000,000-407,000,000-948,000,000
Net Income Margin-188.6%-0.030.030.01-0.05-
Free Cahsflow32.9%-946,000,000-1,409,000,000409,000,000671,000,000-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-2.3%25,68626,29828,17129,09029,202
  Current Assets5.9%4,2474,0105,4175,8365,607
    Cash Equivalents16.0%5644866591,249582
  Inventory3.2%1,0901,0561,0731,045993
  Net PPE6.2%1,6001,5071,5451,5791,598
  Goodwill-4.1%11,54712,04412,26612,42712,457
Liabilities-1.7%25,42625,86527,91829,23129,236
  Current Liabilities2.9%3,9413,8314,9974,7745,198
  Long Term Debt-5.8%21,81423,16822,654--
    LT Debt, Current5.1%432411150--
    LT Debt, Non Current-2.3%20,33420,80421,66423,16822,654
Shareholder's Equity2.8%260253-34.00--
  Retained Earnings-4.7%-9,186-8,776-9,175-9,030-8,961
  Additional Paid-In Capital23.3%159129104415462
Accumulated Depreciation-1,820----
Shares Outstanding0.0%362362362361359
Minority Interest-0.6%95295894675.0072.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations38.3%-728-1,1796489201,426
  Share Based Compensation1.6%126124124129128
Cashflow From Investing-22.7%-303-247394409409
Cashflow From Financing-715.6%-47477.00-1,044-802-1,513

Risks for BHC

What is the probability of a big loss on BHC?

97.3%


Probability that Bausch Health Companies stock will be more than 20% underwater in next one year

72.7%


Probability that Bausch Health Companies stock will be more than 30% underwater in next one year.

36.9%


Probability that Bausch Health Companies stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BHC drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Bausch Health Companies was unfortunately bought at previous high price.

Drawdowns

Returns for BHC

Cumulative Returns on BHC

-20.5%


10-Year Cumulative Returns

-18.5%


7-Year Cumulative Returns

-13.5%


5-Year Cumulative Returns

-17.5%


3-Year Cumulative Returns

What are the long-term rolling returns for BHC?

FIve years rolling returns for Bausch Health Companies.

Annualized Returns

Which funds bought or sold BHC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-06
Rockefeller Capital Management L.P.
unchanged
-
-4,000
41,000
-%
2023-02-27
Parallax Volatility Advisers, L.P.
new
-
2,905,620
2,905,620
-%
2023-02-24
NATIXIS
added
97.72
44,216,900
99,336,900
0.56%
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
reduced
-18.79
-44,912
128,088
-%
2023-02-17
TRUIST FINANCIAL CORP
reduced
-8.35
-14,071
68,929
-%
2023-02-17
Coppell Advisory Solutions Corp.
new
-
1,256
1,256
-%
2023-02-16
MAVERICK CAPITAL LTD
sold off
-100
-278,000
-
-%
2023-02-15
NOMURA HOLDINGS INC
reduced
-28.3
-40,001,000
74,118,000
0.30%
2023-02-15
GABELLI & Co INVESTMENT ADVISERS, INC.
added
20.67
10,668
113,668
0.02%
2023-02-15
BERKSHIRE ASSET MANAGEMENT LLC/PA
reduced
-9.24
-14,176
67,824
-%

1–10 of 40

Latest Funds Activity

Are funds buying BHC calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own BHC
No. of Funds

Bausch Health Companies News

Yahoo Finance

12 Best Biotech Stocks To Buy Under $20.

Yahoo Finance,
2 days ago

The Motley Fool Canada

Yahoo Finance

Schedule 13G FIlings of Bausch Health Companies

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
nomura holdings inc
3.6%
13,030,352
SC 13G/A
Feb 13, 2023
goldentree asset management lp
5.4%
19,421,054
SC 13G
May 13, 2022
va partners i, llc
4.0%
14,430,901
SC 13D/A
Feb 14, 2022
nomura holdings inc
5.4%
19,515,079
SC 13G
Dec 13, 2021
glenview capital management, llc
4.75%
17,078,657
SC 13D/A
Jun 21, 2021
va partners i, llc
5.0%
17,941,603
SC 13D/A
Apr 23, 2021
meruelo alex
5.51%
19,604,777
SC 13G
Mar 16, 2021
icahn carl c
3.98%
14,169,189
SC 13D/A
Mar 11, 2021
icahn carl c
3.98%
14,169,189
SC 13D/A
Feb 24, 2021
icahn carl c
-
0
SC 13D/A

BHC Fair Value

Recent SEC filings of Bausch Health Companies

View All Filings
Date Filed Form Type Document
Mar 07, 2023
4/A
Insider Trading
Mar 06, 2023
144
Notice of Insider Sale Intent
Mar 06, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 01, 2023
4
Insider Trading
Mar 01, 2023
4
Insider Trading
Mar 01, 2023
8-K
Current Report
Feb 23, 2023
8-K
Current Report

Latest Insider Trading transactions for BHC

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-06
Carson Seana
sold (taxes)
-4,539
9.17
-495
evp, general counsel
2023-03-06
Carson Seana
sold
-4,539
9.17
-495
evp, general counsel
2023-03-03
APPIO THOMAS
sold (taxes)
-93,203
9.16
-10,175
chief executive officer
2023-03-03
Carson Seana
sold
-7,285
9.34
-780
evp, general counsel
2023-03-03
Carson Seana
sold (taxes)
-42,093
9.19065
-4,580
evp, general counsel
2023-03-02
Vadaketh Tom George
sold (taxes)
-37,009
9.25
-4,001
evp, chief financial officer
2023-03-02
Vadaketh Tom George
acquired
-
-
142,678
evp, chief financial officer
2023-03-02
Carson Seana
acquired
-
-
95,119
evp, general counsel
2023-03-02
APPIO THOMAS
acquired
-
-
523,155
chief executive officer
2023-03-02
Carson Seana
sold (taxes)
-55,444
9.25
-5,994
evp, general counsel

1–10 of 50

Robert N. Power
19100
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

BHC Income Statement

2022-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenues   
Revenues$ 8,124$ 8,434$ 8,027
Expenses   
Selling, general and administrative2,6252,6242,367
Research and development529465452
Amortization of intangible assets1,2151,3751,645
Goodwill impairments8244690
Asset impairments, including loss on assets held for sale15234114
Restructuring, integration, separation and IPO costs635022
Other expense, net35373502
Total Expenses7,6707,9847,351
Operating income454450676
Interest income14713
Interest expense(1,464)(1,426)(1,534)
Gain (loss) on extinguishment of debt875(62)(59)
Foreign exchange and other(8)7(30)
Loss before income taxes(129)(1,024)(934)
(Provision for) benefit from income taxes(83)87375
Net loss(212)(937)(559)
Net income attributable to noncontrolling interest(13)(11)(1)
Net loss attributable to Bausch Health Companies Inc.$ (225)$ (948)$ (560)
Basic loss per share attributable to Bausch Health Companies Inc. (in dollars per share)$ (0.62)$ (2.64)$ (1.58)
Diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share)$ (0.62)$ (2.64)$ (1.58)
Basic weighted-average common shares (in shares)362,000358,900355,000
Diluted weighted-average common shares (in shares)362,000358,900355,000
Product sales   
Revenues   
Revenues$ 8,046$ 8,342$ 7,924
Expenses   
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues2,3362,3612,202
Other revenues   
Revenues   
Revenues7892103
Expenses   
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues$ 28$ 33$ 47

BHC Balance Sheet

2022-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 564$ 582
Restricted cash and other settlement deposits271,537
Trade receivables, net1,7901,775
Inventories, net1,090993
Prepaid expenses and other current assets776720
Total current assets4,2475,607
Property, plant and equipment, net1,6001,598
Intangible assets, net5,8006,948
Goodwill11,54712,457
Deferred tax assets, net2,1662,252
Other non-current assets326340
Total assets25,68629,202
Current liabilities:  
Accounts payable521407
Accrued and other current liabilities2,9884,791
Current portion of long-term debt4320
Total current liabilities3,9415,198
Acquisition-related contingent consideration208202
Non-current portion of long-term debt20,33422,654
Deferred tax liabilities, net202529
Other non-current liabilities741653
Total liabilities25,42629,236
Commitments and contingencies (Notes 20 and 21)
Equity (Deficit)  
Common shares, no par value, unlimited shares authorized, 361,898,846 and 359,405,748 issued and outstanding at December 31, 2022 and 2021, respectively10,39110,317
Additional paid-in capital159462
Accumulated deficit(9,186)(8,961)
Accumulated other comprehensive loss(2,056)(1,924)
Total Bausch Health Companies Inc. shareholders’ deficit(692)(106)
Noncontrolling interest95272
Total equity (deficit)260(34)
Total liabilities and equity (deficit)$ 25,686$ 29,202